<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Microbes Infect</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Microbes Infect</journal-id><journal-title-group><journal-title>Emerging Microbes &#x00026; Infections</journal-title></journal-title-group><issn pub-type="epub">2222-1751</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7448857</article-id><article-id pub-id-type="publisher-id">1772676</article-id><article-id pub-id-type="doi">10.1080/22221751.2020.1772676</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Letter</subject></subj-group><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture</article-title><alt-title alt-title-type="right-running-head">Emerging Microbes &#x00026; Infections</alt-title><alt-title alt-title-type="left-running-head">Y.-N. Zhang et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Ya-Nan</given-names></name><xref ref-type="aff" rid="AF1">a</xref><xref ref-type="aff" rid="AF5">e</xref><xref ref-type="author-notes" rid="an1">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Qiu-Yan</given-names></name><xref ref-type="aff" rid="AF2">b</xref><xref ref-type="aff" rid="AF3">c</xref><xref ref-type="author-notes" rid="an1">*</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiao-Dan</given-names></name><xref ref-type="aff" rid="AF1">a</xref><xref ref-type="aff" rid="AF4">d</xref><xref ref-type="author-notes" rid="an1">*</xref></contrib><contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="AF1">a</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Shu-Qi</given-names></name><xref ref-type="aff" rid="AF1">a</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhen</given-names></name><xref ref-type="aff" rid="AF6">f</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhe-Rui</given-names></name><xref ref-type="aff" rid="AF1">a</xref><xref ref-type="aff" rid="AF5">e</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Cheng-Lin</given-names></name><xref ref-type="aff" rid="AF1">a</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xing-Lou</given-names></name><xref ref-type="aff" rid="AF1">a</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Hong-Ping</given-names></name><xref ref-type="aff" rid="AF1">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3234-9616</contrib-id><name><surname>Yuan</surname><given-names>Zhi-Ming</given-names></name><xref ref-type="aff" rid="AF1">a</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Han-Qing</given-names></name><xref ref-type="aff" rid="AF1">a</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8895-3679</contrib-id><name><surname>Zhang</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="AF1">a</xref><xref ref-type="aff" rid="AF2">b</xref><xref ref-type="aff" rid="AF3">c</xref><xref ref-type="aff" rid="AF6">f</xref><xref ref-type="corresp" rid="cor2"/></contrib><aff id="AF1"><label>a</label><institution>Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences</institution>, <city>Wuhan</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF2"><label>b</label><institution>The Joint Center of Translational Precision Medicine, Guangzhou Institute of Pediatrics, Guangzhou Women and Children&#x02019;s Medical Center</institution>, <city>Guangzhou</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF3"><label>c</label><institution>The Joint Center of Translational Precision Medicine, Wuhan Institute of Virology, Chinese Academy of Sciences</institution>, <city>Wuhan</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF4"><label>d</label><institution>School of Medicine, Hunan Normal University</institution>, <city>Changsha</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF5"><label>e</label><institution>University of Chinese Academy of Sciences</institution>, <city>Beijing</city>, <country>People&#x02019;s Republic of China</country></aff><aff id="AF6"><label>f</label><institution>Drug Discovery Center for Infectious Disease, Nankai University</institution>, <city>Tianjin</city>, <country>People&#x02019;s Republic of China</country></aff></contrib-group><author-notes><corresp id="cor1"><label>CONTACT</label> Han-Qing Ye <email xlink:href="yehq@wh.iov.cn">yehq@wh.iov.cn</email><institution>Wuhan Institute of Virology, Chinese Academy of Sciences</institution>, <city>Wuhan</city><postal-code>430071</postal-code>, <country>People&#x02019;s Republic of China</country></corresp><corresp id="cor2">Bo Zhang <email xlink:href="zhangbo@wh.iov.cn">zhangbo@wh.iov.cn</email><institution>Wuhan Institute of Virology, Chinese Academy of Sciences</institution>, <city>Wuhan</city><postal-code>430071</postal-code>, <country>People&#x02019;s Republic of China</country></corresp><fn id="an1"><label>*</label><p>These authors have equal contribution to this study.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>2</day><month>6</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>9</volume><issue>1</issue><fpage seq="135">1170</fpage><lpage>1173</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="vor">http://creativecommons.org/licenses/by/4.0/</ali:license_ref></license></permissions><self-uri content-type="pdf" xlink:href="TEMI_9_1772676.pdf"/><abstract><title>ABSTRACT</title><p>The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined the antiviral abilities of three broad-spectrum antiviral compounds gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. We found that all three tested compounds inhibited viral replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of gemcitabine was suppressed efficiently by the cytidine nucleosides. Additionally, combination of gemcitabine with oxysophoridine had an additive antiviral effect against SARS-CoV-2. Our results demonstrate that broad-spectrum antiviral compounds may have a priority for the screening of antiviral compounds against newly emerging viruses to control viral infection.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Novel coronavirus</kwd><kwd>alkaloid</kwd><kwd>broad-spectrum antiviral</kwd><kwd>2019-nCoV</kwd><kwd>SARS-CoV-2</kwd></kwd-group><counts><fig-count count="1"/><table-count count="0"/><equation-count count="0"/><ref-count count="15"/><page-count count="4"/></counts></article-meta></front><body><p>Since the late 2019 when a cluster of pneumonia associated with the emerging novel coronavirus, SARS-CoV-2 was reported in Wuhan, China. Since then, the outbreak has spread rapidly and developed into a global pandemic. At the time the paper was submitted, about 210 countries and territories around the world have reported more than 2.9 million confirmed cases of SARS-CoV-2 including more than 203,289 deaths (<ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/#countries">https://www.worldometers.info/coronavirus/#countries</ext-link>). Currently, there is no antiviral therapy or vaccine available for human usage. It is urgent to develop some antiviral compounds for the treatment of SARS-CoV-2 infection because of its high infectivity and morbidity and its ability to cause epidemics worldwide. Different compounds, such as remdesivir and chloroquine have been reported to inhibit SARS-CoV-2 replication effectively <italic>in vitro</italic> [<xref rid="CIT0001" ref-type="bibr">1</xref>]. The efficacy of these drugs for SARS-CoV-2 is still under investigation by clinical experiments.</p><p>In this study, we tested antiviral activity of gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 infection in cell culture, and chloroquine was used as a positive control [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Vero-E6 cells infected with SARS-CoV-2 (WIV04) [<xref rid="CIT0002" ref-type="bibr">2</xref>] at a multiplicity of infection (MOI) of 0.005 were treated with increased concentrations of compounds. The viral RNAs in cell culture media were quantified with quantitative real-time RT-PCR (qRT-PCR). All these three compounds exhibited dose-dependent inhibition of 2019-CoV replication in infected cells as chloroquine (<xref rid="F0001" ref-type="fig">Figure 1</xref>(A)). The EC<sub>50</sub> values of gemcitabine, lycorine, oxysophoridine and chloroquine were 1.24, 0.31, 0.18 and 1.36&#x02005;&#x003bc;M, respectively. To confirm that the inhibition of viral replication was not due to compound-mediated cytotoxicity, a cell proliferation-based cytotoxicity assay was performed. As shown in <xref rid="F0001" ref-type="fig">Figure 1</xref>(A), the CC<sub>50</sub> (50% cytotoxic concentration) values were all above 40&#x02005;&#x003bc;M. The selectivity index (SI[CC<sub>50</sub>/EC<sub>50</sub>]) in Vero cells were above 33, 129, 222 and 30, respectively. We then performed indirect immunofluorescence assay (IFA) for viral protein expression using anti-NP antibody to further verify the antiviral activity of all the three compounds. The number of IFA positive cells indicated the capability of virus replication and spreading within infected cells. Comparing with DMSO treated group, compounds treated groups showed significantly decreased positive cells with increased concentrations of compounds (<xref rid="F0001" ref-type="fig">Figure 1</xref>(B)). Consistently, the inhibitory effects of these compounds on SARS-CoV-2 replication were also displayed through dose-dependent rescuing CPE in infected cells (<xref rid="F0001" ref-type="fig">Figure 1</xref>(C)). Additionally, all three compounds could efficiently inhibit SARS-CoV-2 in Huh-7 cells (<xref rid="F0001" ref-type="fig">Figure 1</xref>(D)), which indicated that their antiviral activities were not cell type dependent. Given the successful application of antiviral combination therapy for treatment of HIV and enterovirus infection, the antiviral effect of gemcitabine in combination with increased concentrations of oxysophoridine was also evaluated in Vero-E6 cells (<xref rid="F0001" ref-type="fig">Figure 1</xref>(E)). The expected additive inhibitory effects were observed with the combination of gemcitabine and oxysophoridine.
<fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>The antiviral activities of gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. (A) Dose-dependent inhibition of gemcitabine, lycorine and oxysophoridine on SARS-CoV-2 infectivity. Vero-E6 cells infected with SARS-CoV-2 at an MOI of 0.005 were treated with increasing concentration of compounds for 24 hours. Real-time RT-PCR was used to quantify viral RNA copy numbers in culture media. The cytotoxicity of the compounds on Vero-E6 cells was examined with CCK-8 assay kit. Antiviral activity and cytotoxicity are shown in pink and blue, respectively. The EC<sub>50</sub> and CC<sub>50</sub> are displayed in the upper right corner for each compound. At least three independent experiments were performed, and one representative experiment was presented. The data were represented as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) of the triplicate measurements. (B) IFA analysis of the inhibition of the compounds on SARS-CoV-2 replication. At 24&#x02005;hpi, the infected cells treated with different concentration of compounds were fixed and subjected to IFA using the primary antibody against NP protein of SARS-CoV-2. (C) Characterization of antiviral activities based on CPE-reduction assay. At 48 hpi, the CPE in infected Vero-E6 cells was visualized under light microscope. (D) Dose-dependent inhibition of gemcitabine, lycorine and oxysophoridine on SARS-CoV-2 infectivity in Huh-7 cells. The cells infected with SARS-CoV-2 at an MOI of 0.001 were treated with increasing concentration of compounds for 72 hours, and viral RNA copy numbers in culture media were quantified through real-time RT-PCR. The asterisks denote statistical differences between indicated groups.*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.1, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001 (One-way ANOVA with Kruskal-Wallis test). n.s. indicates no statistical differences. (E) Additive anti-SARS-CoV-2 effect of gemcitabine in combination with different concentrations of oxysophoridine. The asterisks denote statistical differences between indicated groups.*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.1, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001(Two-way ANOVA). n.s. indicates no statistical differences. (F) Suppression of the antiviral activity of gemcitabine by cytidine. Vero-E6 cells were infected with SARS-CoV-2 and simultaneously treated with 10&#x02005;&#x003bc;M gemcitabine plus different concentrations of cytidine or uridine. The asterisks denote statistical differences between indicated groups.*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.1, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001 (Student&#x02019;s <italic>t</italic>-test). n.s. indicates no statistical differences. All above experiments were performed at least three independent, and one representative experiment was presented. All the Data were represented as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD).</p></caption><alternatives><graphic specific-use="web-only" content-type="color" xlink:href="TEMI_A_1772676_F0001_OC"/><graphic specific-use="print-only" content-type="black-white" xlink:href="TEMI_A_1772676_F0001_PB"/></alternatives></fig></p><p>Gemcitabine is a cytidine analog approved by the FDA for the treatment of various cancers [<xref rid="CIT0003" ref-type="bibr">3</xref>]. Increasing evidence has shown that gemcitabine is an effective broad spectrum antiviral agent against multiple RNA viruses which include Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) [<xref rid="CIT0004" ref-type="bibr">4</xref>], Zika virus [<xref rid="CIT0005" ref-type="bibr">5</xref>], influenza virus [<xref rid="CIT0006" ref-type="bibr">6</xref>] and enterovirus. Gemcitabine inhibits both MERS-CoV and SARS-CoV with micromolar EC50s (1.22&#x02005;&#x003bc;M and 4.96&#x02005;&#x003bc;M, respectively) [<xref rid="CIT0004" ref-type="bibr">4</xref>], which are similar to the EC<sub>50</sub> of SARS-CoV-2 (1.24&#x02005;&#x003bc;M) in our study. It is thought that gemcitabine might exert its antiviral activities by targeting the salvage pathway of pyrimidine biosynthesis and stimulating innate immunity, at least in the cases of enterovirus [<xref rid="CIT0007" ref-type="bibr">7</xref>] and influenza virus [<xref rid="CIT0006" ref-type="bibr">6</xref>]. To examine whether it acts by the same antiviral mechanism against SARS-CoV-2, we added additional natural nucleosides (C and U) with gemcitabine in cell culture. Similar to the previous results observed in enterovirus [<xref rid="CIT0007" ref-type="bibr">7</xref>], the addition of exogenous cytidine significantly inhibited the antiviral activity of gemcitabine against SARS-CoV-2 (<xref rid="F0001" ref-type="fig">Figure 1</xref>(F)). Our results thus indicated that gemcitabine may inhibit SARS-CoV-2 replication through the modulation of nucleotide biosynthesis, the same mechanism as did in enterovirus [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Although we are unable to draw definitive conclusions regarding the efficacy of gemcitabine against SARS-CoV-2 due to the lack of <italic>in vivo</italic> animal data, its antiviral efficiencies have been demonstrated in the mice models of enterovirus and human immunodeficiency virus (HIV) [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Additionally, the mean peak plasma concentration of gemcitabine observed in patients with advanced non-small cell lung cancer (NSCLC) could reach 17&#x02005;&#x000b5;M after bronchial artery infusion or intravenous infusion [<xref rid="CIT0008" ref-type="bibr">8</xref>], which is much higher than EC<sub>50</sub> of 1.21 &#x003bc;M in Vero-E6 cell. Altogether, these results support the therapeutic potential of gemcitabine as effective antivirals with low toxicity against SARS-CoV-2. Further <italic>in vivo</italic> evaluation about the antiviral activity of gemcitabine against SARS-CoV-2 infection is going to be carried out in the near future, which will accelerate its application in clinical trials.</p><p>Different with gemcitabine, both oxysophoridine and lycorine are bioactive alkaloids derived from Chinese herbal medicines. Alkaloids are a group of naturally occurring chemical compounds that contain mostly basic nitrogen atoms [<xref rid="CIT0009" ref-type="bibr">9</xref>]. Oxysophoridine is an alkaloid extracted from Sophora alopecuroides Linn. Many studies based on <italic>in vitro</italic> cellular or <italic>in vivo</italic> animal assays have shown that oxysophoridine has various pharmacological activities, including suppression of the growth of hepatocellular carcinoma [<xref rid="CIT0010" ref-type="bibr">10</xref>] and colorectal cancer cells [<xref rid="CIT0011" ref-type="bibr">11</xref>] by regulating apoptosis associated with the Bcl-2/Bax/caspase-3 signalling pathway, and alleviation of spinal cord injury via anti-inflammatory, anti-oxidative stress and anti-apoptosis effects [<xref rid="CIT0012" ref-type="bibr">12</xref>]. In the present study, we found a new indication for oxysophoridine as a compound inhibiting SARS-CoV-2 infection in cell culture. To our knowledge, this is the first time to report the antiviral activity of oxysophoridine. We also found that oxysophoridine could efficiently inhibit flavivirus and alphavirus replication (unpublished data), which indicated that oxysophoridine may have a broad-spectrum antiviral activity against RNA viruses.</p><p>Lycorine is an active alkaloid abundant in Amaryllidaceae with a wide range of biological functions for cancer and infectious diseases treatment [<xref rid="CIT0013" ref-type="bibr">13</xref>]. Unlike oxysophoridine, lycorine has been well known to exhibit antiviral activities against enterovirus, flaviviruses, HIV-1, SARS-CoV and hepatitis C virus. Regarding the exact antiviral mechanism of lycorine, however, it remains elusive. Different drug resistant mutations of lycorine have been identified within the viral protease of enterovirus or nonstructural protein 2&#x02005;K of West Nile virus. Meanwhile, it was reported that lycorine was able to (i) inhibit the export of influenza virus nucleoprotein from the nucleus [<xref rid="CIT0014" ref-type="bibr">14</xref>], and (ii) downregulate autophagy [<xref rid="CIT0015" ref-type="bibr">15</xref>] or block the elongation of viral RNA translation during EV71 infection [<xref rid="CIT0013" ref-type="bibr">13</xref>] to suppress viral replication. Altogether, we speculate that the mechanism behind the anti-SARS-CoV-2 activity of lycorine is probably attributed to modulating host factors instead of directly targeting viral factors.</p><p>Overall, more information is needed regarding anti-SARS-CoV-2 issues of both oxysophoridine and lycorine including antiviral mechanisms, the safety profile and toxicological evaluation in future study.</p></body><back><ack><title>Acknowledgements</title><p>This work was supported by the National Key Research and Development Program of China (2018YFA0507201). The experiments related to SARS-CoV-2 are completed at National Biosafety Laboratory, Wuhan, Chinese Academy of Sciences. We are particularly grateful to Tao Du and Lun Wang from Zhengdian Biosafety Level 3 Laboratory and the running team of the laboratory for their work.</p></ack><sec sec-type="COI-statement" id="S002"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>G.</given-names></name></person-group>
<year>2020</year>
<article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title>. <source>Cell Res</source>. DOI:<pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>XL</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>XG</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Si</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>MQ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>XR</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>XS</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>QJ</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>FX</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>GF</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>ZL.</given-names></name></person-group>
<year>2020</year>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source>. DOI:<pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>.</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>S.</given-names></name></person-group>
<article-title>Gemcitabine and nucleos(t)ide synthesis inhibitors are broad-spectrum antiviral drugs that activate innate immunity</article-title>. <source>Viruses</source>. <year>2018</year>;<volume>10</volume>(<issue>4</issue>):<fpage>211</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v10040211</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyall</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Coleman</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Hart</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Venkataraman</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Holbrook</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Kindrachuk</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Olinger</surname><given-names>GG</given-names><suffix>Jr.</suffix></name>, <name name-style="western"><surname>Jahrling</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Laidlaw</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Johansen</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Lear-Rooney</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Glass</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Hensley</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Frieman</surname><given-names>MB.</given-names></name></person-group>
<year>2014</year>
<article-title>Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>58</volume>:<fpage>4885</fpage>-<lpage>93</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.03036-14</pub-id><pub-id pub-id-type="pmid">24841273</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuivanen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bespalov</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Nandania</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism</article-title>. <source>Antiviral Res</source>. <year>2017</year>;<volume>139</volume>:<fpage>117</fpage>&#x02013;<lpage>128</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.12.022</pub-id><pub-id pub-id-type="pmid">28049006</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denisova</surname><given-names>OV</given-names></name>, <name name-style="western"><surname>Kakkola</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>:<fpage>35324</fpage>&#x02013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M112.392142</pub-id><pub-id pub-id-type="pmid">22910914</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Jang</surname><given-names>KS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>:<fpage>115315</fpage>&#x02013;<lpage>115325</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.23258</pub-id><pub-id pub-id-type="pmid">29383162</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alharbi</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Kratzke</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>D&#x02019;Cunha</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2019</year>;<volume>83</volume>:<fpage>387</fpage>&#x02013;<lpage>391</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00280-018-3757-7</pub-id><pub-id pub-id-type="pmid">30542769</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>FH</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>ZX</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>PP</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Traditional Chinese medicine and related active compounds: a review of their role on hepatitis B virus infection</article-title>. <source>Drug Discov Ther</source>. <year>2013</year>;<volume>7</volume>:<fpage>212</fpage>&#x02013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.5582/ddt.2013.v7.6.212</pub-id><pub-id pub-id-type="pmid">24423652</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>XQ</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: in vivo and cDNA microarray studies</article-title>. <source>Chin J Integr Med</source>. <year>2012</year>;<volume>18</volume>:<fpage>209</fpage>&#x02013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11655-012-1001-6</pub-id><pub-id pub-id-type="pmid">22466946</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>In vivo and in vitro induction of the apoptotic effects of oxysophoridine on colorectal cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway</article-title>. <source>Oncol Lett</source>. <year>2017</year>;<volume>14</volume>:<fpage>8000</fpage>&#x02013;<lpage>8006</lpage>.<pub-id pub-id-type="pmid">29344242</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Oxysophoridine rescues spinal cord injury via antiinflammatory, antioxidative stress and antiapoptosis effects</article-title>. <source>Mol Med Rep</source>. <year>2018</year>;<volume>17</volume>:<fpage>2523</fpage>&#x02013;<lpage>2528</lpage>.<pub-id pub-id-type="pmid">29207118</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication</article-title>. <source>Virol J</source>. <year>2011</year>;<volume>8</volume>:<fpage>483</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1743-422X-8-483</pub-id><pub-id pub-id-type="pmid">22029605</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Qi</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Amaryllidaceae alkaloids inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic avian influenza virus H5N1</article-title>. <source>Infl Other Respir Viruses</source>. <year>2013</year>;<volume>7</volume>:<fpage>922</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1111/irv.12035</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lycorine derivative LY-55 inhibits EV71 and CVA16 replication through downregulating autophagy</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2019</year>;<volume>9</volume>:<fpage>277</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2019.00277</pub-id><pub-id pub-id-type="pmid">31448243</pub-id></mixed-citation></ref></ref-list></back></article>